课题基金 / 基金详情

eIF2 phosphatase inhibitors in the treatment of Trastuzumab-resistant breast cancer.

eIF2 phosphatase inhibitors in the treatment of Trastuzumab-resistant breast cancer.
eIF2 磷酸酶抑制剂治疗曲妥珠单抗耐药乳腺癌。
批准号：
407421
负责人：
Koromilas Antonis E
金额：
$4.37万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-02-01 至 2021-02-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=407421&lang=en
关键词：
Breast Cancer

项目摘要

项目成果

Koromilas Antonis E的其他基金

相似基金

相关文献

中文摘要
翻译
HER2+乳腺肿瘤具有高度侵袭性和转移性。一种名为曲妥珠单抗或赫赛汀的针对HER2+乳腺癌的特定药物被用来显著提高患者在单一或联合化疗药物治疗中的生存机会。
英文摘要
HER2+ breast tumors are highly invasive and metastatic. A specific drug for HER2+ breast cancers called Trastuzumab or Herceptin is used to substantially increase the chance of patient survival in single or combined treatments with chemotherapeutic drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Deciphering the metabolic and tumorigenic functions of STAT1 in mutant KRAS cancer.
The implication of the adaptive arm of the integrated stress response in KRAS lung cancer.
Mechanisms and therapeutic implications of PKR and eIF2 phosphorylation in HER2 breast tumor suppression.
The function of eIF2alpha phosphorylation in Ras signaling and lung tumorigenesis.
海外基金